134 related articles for article (PubMed ID: 1350077)
21. Central antiemetic effects of AS-8112, a dopamine D2, D3, and 5-HT(3) receptor antagonist, in ferrets.
Yoshikawa T; Yoshida N; Oka M
Eur J Pharmacol; 2001 Nov; 431(3):361-4. PubMed ID: 11730730
[TBL] [Abstract][Full Text] [Related]
22. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
Gidda JS; Evans DC; Cohen ML; Wong DT; Robertson DW; Parli CJ
J Pharmacol Exp Ther; 1995 May; 273(2):695-701. PubMed ID: 7752072
[TBL] [Abstract][Full Text] [Related]
23. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
Fernández AG; Puig J; Beleta J; Doménech T; Bou J; Berga P; Gristwood RW; Roberts DJ
Eur J Pharmacol; 1992 Nov; 222(2-3):257-64. PubMed ID: 1451737
[TBL] [Abstract][Full Text] [Related]
24. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret.
King GL; Landauer MR
J Pharmacol Exp Ther; 1990 Jun; 253(3):1026-33. PubMed ID: 2359014
[TBL] [Abstract][Full Text] [Related]
25. The antiemetic profile of zacopride.
Smith WL; Alphin RS; Jackson CB; Sancilio LF
J Pharm Pharmacol; 1989 Feb; 41(2):101-5. PubMed ID: 2568416
[TBL] [Abstract][Full Text] [Related]
26. Differential roles for NMDA and non-NMDA receptor subtypes in baroreceptor afferent integration in the nucleus of the solitary tract of the rat.
Zhang J; Mifflin SW
J Physiol; 1998 Sep; 511 ( Pt 3)(Pt 3):733-45. PubMed ID: 9714856
[TBL] [Abstract][Full Text] [Related]
27. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.
Higgins GA; Kilpatrick GJ; Bunce KT; Jones BJ; Tyers MB
Br J Pharmacol; 1989 May; 97(1):247-55. PubMed ID: 2720310
[TBL] [Abstract][Full Text] [Related]
28. RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.
Eglen RM; Lee CH; Smith WL; Johnson LG; Whiting RL; Hegde SS
J Pharmacol Exp Ther; 1993 Aug; 266(2):535-43. PubMed ID: 8355189
[TBL] [Abstract][Full Text] [Related]
29. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.
Warneck JB; Cheng FH; Barnes MJ; Mills JS; Montana JG; Naylor RJ; Ngan MP; Wai MK; Daiss JO; Tacke R; Rudd JA
Toxicol Appl Pharmacol; 2008 Nov; 232(3):369-75. PubMed ID: 18675289
[TBL] [Abstract][Full Text] [Related]
30. NBQX, an improved non-NMDA antagonist studied in retinal ganglion cells.
Yu W; Miller RF
Brain Res; 1995 Sep; 692(1-2):190-4. PubMed ID: 8548303
[TBL] [Abstract][Full Text] [Related]
31. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
Tattersall FD; Rycroft W; Francis B; Pearce D; Merchant K; MacLeod AM; Ladduwahetty T; Keown L; Swain C; Baker R; Cascieri M; Ber E; Metzger J; MacIntyre DE; Hill RG; Hargreaves RJ
Neuropharmacology; 1996; 35(8):1121-9. PubMed ID: 9121615
[TBL] [Abstract][Full Text] [Related]
32. Serotonin antagonists: a new class of antiemetic agents.
Hesketh PJ; Gandara DR
J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
[TBL] [Abstract][Full Text] [Related]
33. Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret.
Rudd JA; Naylor RJ
Neuropharmacology; 1994 Dec; 33(12):1607-8. PubMed ID: 7760983
[TBL] [Abstract][Full Text] [Related]
34. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F.
Mele PC; McDonough JR; McLean DB; O'Halloran KP
Eur J Pharmacol; 1992 Aug; 218(2-3):229-36. PubMed ID: 1330594
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.
Miner WD; Sanger GJ
Br J Pharmacol; 1986 Jul; 88(3):497-9. PubMed ID: 3742146
[TBL] [Abstract][Full Text] [Related]
37. Studies on the emetic and antiemetic properties of zacopride and its enantiomers.
Sancilio LF; Pinkus LM; Jackson CB; Munson HR
Eur J Pharmacol; 1991 Jan; 192(3):365-9. PubMed ID: 2055236
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets.
Kamato T; Ito H; Nagakura Y; Nishida A; Yuki H; Yamano M; Miyata K
Eur J Pharmacol; 1993 Jul; 238(2-3):369-76. PubMed ID: 8405104
[TBL] [Abstract][Full Text] [Related]
39. Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs.
Gullikson GW; Loeffler RF; Viriña MA
J Pharmacol Exp Ther; 1991 Jul; 258(1):103-10. PubMed ID: 2072288
[TBL] [Abstract][Full Text] [Related]
40. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
